Amount of maternal rotavirus-specific antibodies influence the outcome of rotavirus vaccination of newborn mice with virus-like particles

Vaccine

Volumn 26, Issue 6, 2008, Pages 778-785

  Johansson, E ^a,b   Istrate, C ^a,c,d   Charpilienne, A ^e   Cohen, J ^e   Hinkula, J ^c   Poncet, D ^e   Svensson, L ^c   Johansen, K ^a,b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA   (Portugal)

^e INSTITUTE FOR INTEGRATIVE BIOLOGY OF THE CELL I2BC   (France)

Author keywords

Neonatal immunization; PCPP; Rotavirus; Virus like particles

Indexed keywords

IMMUNOGLOBULIN G; MATERNAL ANTIBODY; ROTAVIRUS VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NEWBORN; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGENY; ROTAVIRUS; VACCINATION; VIRUS INFECTION; VIRUS LIKE AGENT;

EID: 38349070942     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.089     Document Type: Article

References (54)

1. Offit P.A., and Clark H.F. Protection against rotavirus-induced gastroenteritis in a murine model by passively acquired gastrointestinal but not circulating antibodies. J Virol 54 1 (1985) 58-64
2. Saif L.J., Redman D.R., Smith K.L., and Theil K.W. Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from immunized or nonimmunized cows. Infect Immun 41 3 (1983) 1118-1131
3. Hodgins D.C., Kang S.Y., deArriba L., Parreno V., Ward L.A., Yuan L., et al. Effects of maternal antibodies on protection and development of antibody responses to human rotavirus in gnotobiotic pigs. J Virol 73 1 (1999) 186-197
4. Conner M.E., Crawford S.E., Barone C., and Estes M.K. Rotavirus vaccine administered parenterally induces protective immunity. J Virol 67 11 (1993) 6633-6641
5. Westerman L.E., McClure H.M., Jiang B., Almond J.W., and Glass R.I. Serum IgG mediates mucosal immunity against rotavirus infection. Proc Natl Acad Sci USA 102 20 (2005) 7268-7273
6. Clemens J., Rao M., Ahmed F., Ward R., Huda S., Chakraborty J., et al. Breast-feeding and the risk of life-threatening rotavirus diarrhea: prevention or postponement?. Pediatrics 92 5 (1993) 680-685
7. Turner R.B., and Kelsey D.K. Passive immunization for prevention of rotavirus illness in healthy infants. Pediatr Infect Dis J 12 9 (1993) 718-722
8. Vial P.A., Kotloff K.L., and Losonsky G.A. Molecular epidemiology of rotavirus infection in a room for convalescing newborns. J Infect Dis 157 4 (1988) 668-673
9. Flores J., White L., Blanco M., and Perez-Schael I. Serological response to rotavirus infection in newborn infants. J Med Virol 42 1 (1994) 97-102
10. Goldman A.S. Evolution of the mammary gland defense system and the ontogeny of the immune system. J Mammary Gland Biol Neoplasia 7 3 (2002) 277-289
11. Offit P.A., Clark H.F., Blavat G., and Greenberg H.B. Reassortant rotaviruses containing structural proteins vp3 and vp7 from different parents induce antibodies protective against each parental serotype. J Virol 60 2 (1986) 491-496
12. Parreno V., Hodgins D.C., de Arriba L., Kang S.Y., Yuan L., Ward L.A., et al. Serum and intestinal isotype antibody responses to Wa human rotavirus in gnotobiotic pigs are modulated by maternal antibodies. J Gen Virol 80 Pt 6 (1999) 1417-1428
13. Coulson B.S., Grimwood K., Masendycz P.J., Lund J.S., Mermelstein N., Bishop R.F., et al. Comparison of rotavirus immunoglobulin A coproconversion with other indices of rotavirus infection in a longitudinal study in childhood. J Clin Microbiol 28 6 (1990) 1367-1374
14. Coulson B.S., Grimwood K., Hudson I.L., Barnes G.L., and Bishop R.F. Role of coproantibody in clinical protection of children during reinfection with rotavirus. J Clin Microbiol 30 7 (1992) 1678-1684
15. Matson D.O., O'Ryan M.L., Herrera I., Pickering L.K., and Estes M.K. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis 167 3 (1993) 577-583
16. Johansen K., and Svensson L. Neutralization of rotavirus and recognition of immunologically important epitopes on VP4 and VP7 by human IgA. Arch Virol 142 7 (1997) 1491-1498
17. Bishop R.F., Bugg H.C., Masendycz P.J., Lund J.S., Gorrell R.J., and Barnes G.L. Serum, fecal, and breast milk rotavirus antibodies as indices of infection in mother-infant pairs. J Infect Dis 174 Suppl 1 (1996) S22-S29
18. Yuan L., Ward L.A., Rosen B.I., To T.L., and Saif L.J. Systematic and intestinal antibody-secreting cell responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease. J Virol 70 5 (1996) 3075-3083
19. Johansen K., Schroder U., and Svensson L. Immunogenicity and protective efficacy of a formalin-inactivated rotavirus vaccine combined with lipid adjuvants. Vaccine 21 5/6 (2003) 368-375
20. Blutt S.E., Kirkwood C.D., Parreno V., Warfield K.L., Ciarlet M., Estes M.K., et al. Rotavirus antigenemia and viraemia: a common event?. Lancet 362 9394 (2003) 1445-1449
21. Blutt S., Matson D., Crawford S.E., Staat M., Azimi P., Bennet B., et al. Rotavirus antigenemia in children is associated with viremia. PLoS Med 4 4 (2007) 660-668
22. Azevedo M.S., Yuan L., Jeong K.I., Gonzalez A., Nguyen T.V., Pouly S., et al. Viremia and nasal and rectal shedding of rotavirus in gnotobiotic pigs inoculated with Wa human rotavirus. J Virol 79 9 (2005) 5428-5436
23. Franco M.A., Angel J., and Greenberg H.B. Immunity and correlates of protection for rotavirus vaccines. Vaccine 24 15 (2006) 2718-2731
24. Crawford S.E., Labbe M., Cohen J., Burroughs M.H., Zhou Y.J., and Estes M.K. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J Virol 68 9 (1994) 5945-6022
25. Parez N., Fourgeux C., Mohamed A., Dubuguoy C., Pillot M., Dehee A., et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J Virol 80 4 (2006) 1752-1761
26. Labbe M., Charpilienne A., Crawford S.E., Estes M.K., and Cohen J. Expression of rotavirus VP2 produces empty corelike particles. J Virol 65 6 (1991) 2946-2952
27. Tosser G., Labbe M., Bremont M., and Cohen J. Expression of the major capsid protein VP6 of group C rotavirus and synthesis of chimeric single-shelled particles by using recombinant baculoviruses. J Virol 66 10 (1992) 5825-5831
28. Charpilienne A., Abad M.J., Michelangeli F., Alvarado F., Vasseur M., Cohen J., et al. Solubilized and cleaved VP7, the outer glycoprotein of rotavirus, induces permeabilization of cell membrane vesicles. J Gen Virol 78 Pt 6 (1997) 1367-1371
29. Nejmeddine M., Trugnan G., Sapin C., Kohli E., Svensson L., Lopez S., et al. Rotavirus spike protein VP4 is present at the plasma membrane and is associated with microtubeles in infected cells. J Virol 74 7 (2000) 3313-3320
30. Charpilienne A., Nejmeddine M., Berois M., Parez N., Neumann E., Hewat E., et al. Individual rotavirus-like particles containing 120 molecules of fluorescent protein are visible in living cells. J Biol Chem 276 31 (2001) 29361-29367
31. Andrianov A., Marin A., and Roberts B. Polyphosphazene polyelectrolytes: a link between the formation of non-covalent complexes with antigenic proteins and immunostimulating activity. Biomacromolecules 6 3 (2005) 1375-1379
32. Andrianov A., Svirkin Y., LeGolvan M., and Synthesis. Biologically relevant properties of polyphosphazene polyacids. Biomacromolecules 5 5 (2004) 1999-2006
33. Mutwiri G., Benjamin P., Soita H., Townsend H., Yost R., Roberts B., et al. Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influensa virus antigens. Vaccine 25 (2007) 1204-1213
34. Johansen K., Schroder U., and Svensson L. Immunogenicity and protective efficacy of a formalin-inactivated rotavirus vaccine combined with lipid adjuvants. Vaccine 3565 (2003) 1-8
35. Johansen K. Immune responses related to protection against rotavirus after natural infection and vaccination. Thesis. Stockholm: Karolinska Institute; 1999.
36. Blutt S.E., Warfield K.L., O'Neal C.M., Estes M.K., and Conner M.E. Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs). Vaccine 24 8 (2006) 1170-1179
37. Rowe J., Poolman J.T., Macaubas C., Sly P.D., Loh R., and Holt P.G. Enhancement of vaccine-specific cellular immunity in infants by passively acquired maternal antibody. Vaccine 22 29/30 (2004) 3986-3992
38. VanCott J.L., Prada A.E., McNeal M.M., Stone S.C., Basu M., Huffer Jr. B., et al. Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidates. J Virol 80 10 (2006) 4949-4961
39. Parez N., Garbarg-Chenon A., Fourgeux C., Le Deist F., Servant-Delmas A., Charpilienne A., et al. The VP6 protein of rotavirus interacts with a large fraction of human naive B cells via surface immunoglobulins. J Virol 78 22 (2004) 12489-12496
40. Steele D., Tumbo J., Armah G., Reynders J., Scholtz F., Bos P., et al. Concomitant administration of a live-attenuated oral rotavirus vaccin (RIX4414) with poliovirus vaccines in African infants. 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases ESPID (2005) 204
41. Siegrist C.-A. The challenges of vaccine responses in early life: selected examples. J Comp Pathol 137 (2007) S4-S9
42. Siegrist C.A. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 21 24 (2003) 3406-3412
43. Van Rie A., Wendelboe A.M., and Englund J.A. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J 24 5 Suppl (2005) S62-S65
44. Nguyen T., Yuan L., Azavedo M., Jeong K., Gonzalez A., Iosef C., et al. High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen. Clin Vaccine Immunol 13 4 (2006) 475-485
45. Nguyen T., Yuan L., Azavedo M., Jeong K., Gonzalez A., Iosef C., et al. Low titer maternal antibodies can both enhance and suppress B-cell responses to a combined live attenuated human rotavirus and VLP-ISCOM vaccine. Vaccine 24 13 (2006) 2302-2316
46. Bertolotti-Ciarlet A., Ciarlet M., Crawford S.E., Conner M.E., and Estes M.K. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 21 25/26 (2003) 3885-3900
47. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354 1 (2006) 23-33
48. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354 1 (2006) 11-22
49. Friedman M.G., Segal B., Zedaka R., Sarov B., Margalith M., Bishop R., et al. Serum and salivary responses to oral tetravalent reassortant rotavirus vaccine in newborns. Clin Exp Immunol 92 2 (1993) 194-199
50. Ward R.L., Knowlton D.R., Zito E.T., Davidson B.L., Rappaport R., and Mack M.E. Serologic correlates of immunity in a tetravalent reassortant rotavirus vaccine trial. US Rotavirus Vaccine Efficacy Group. J Infect Dis 176 3 (1997) 570-577
51. Migasena S., Simasathien S., Samakoses R., Pitisuttitham P., Sangaroon P., van Steenis G., et al. Simultaneous administration of oral rhesus-human reassortant tetravalent (RRV-TV) rotavirus vaccine and oral poliovirus vaccine (OPV) in Thai infants. Vaccine 13 2 (1995) 168-174
52. Lanata C.F., Midthun K., Black R.E., Butron B., Huapaya A., Penny M.E., et al. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 174 2 (1996) 268-275
53. Linhares A.C., Gabbay Y.B., Mascarenhas J.D., de Freitas R.B., Oliveira C.S., Bellesi N., et al. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull World Health Organ 74 5 (1996) 491-500
54. Rimer H.C., Wasserman S.S., Flores J., Pichichero M.E., and Losonsky G.A. Rotavirus-specific breast milk antibody in two populations and possible correlates of interference with rhesus rotavirus vaccine seroconversion. J Infect Dis 165 5 (1992) 826-830